These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21922510)

  • 1. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.
    Pollyea DA; Raval A; Kusler B; Gotlib JR; Alizadeh AA; Mitchell BS
    Hematol Oncol; 2011 Sep; 29(3):157-60. PubMed ID: 21922510
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
    Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
    Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
    Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
    Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome].
    Zhang W; Fu R; Wang HQ; Li LJ; Yue LZ; Liu H; Qu W; Liang Y; Wang GJ; Wang XM; Wu YH; Liu H; Song J; Guan J; Xing LM; Shao ZH
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):543-6. PubMed ID: 22943828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.
    Voso MT; Fabiani E; Piciocchi A; Matteucci C; Brandimarte L; Finelli C; Pogliani E; Angelucci E; Fioritoni G; Musto P; Greco M; Criscuolo M; Fianchi L; Vignetti M; Santini V; Hohaus S; Mecucci C; Leone G
    Leukemia; 2011 Dec; 25(12):1910-3. PubMed ID: 21760590
    [No Abstract]   [Full Text] [Related]  

  • 14. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting new molecular genetics in myelodysplastic syndromes.
    Abdel-Wahab O; Figueroa ME
    Hematology Am Soc Hematol Educ Program; 2012; 2012():56-64. PubMed ID: 23233561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
    Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
    Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
    Wang JY; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
    Gurnari C; Pagliuca S; Guan Y; Adema V; Hershberger CE; Ni Y; Awada H; Kongkiatkamon S; Zawit M; Coutinho DF; Zalcberg IR; Ahn JS; Kim HJ; Kim DDH; Minden MD; Jansen JH; Meggendorfer M; Haferlach C; Jha BK; Haferlach T; Maciejewski JP; Visconte V
    Blood Adv; 2022 Jan; 6(1):100-107. PubMed ID: 34768283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in
    Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
    Leuk Lymphoma; 2019 Dec; 60(13):3316-3319. PubMed ID: 31204875
    [No Abstract]   [Full Text] [Related]  

  • 20. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
    Jain P; Tang G; Konoplev SN; Kanagal-Shamanna R; Wang SA; Pemmaraju N; Daver N; Estrov Z
    Am J Hematol; 2016 Mar; 91(3):354-5. PubMed ID: 26437693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.